Phenformin is a potent biguanic OXPHOS complex I inhibitor that has shown greater than 30% tumor growth inhibition in 5 out of 12 pancreatic adenocarcinoma xenograft models (Rajeshkumar et al. 2017). It is more potent than metformin, another OXPHOS complex I inhibitor, which only suppressed tumor growth in 3 out of 12 pancreatic adenocarcinoma xenograft models even at a five-fold higher dose (Rajeshkumar et al. 2017). In contrast to metformin, phenformin does not require a cellular transporter (Iversen et al. 2017) and has been shown to resensitize previously therapy-resistant cancer cells (Matassa et al. 2016). Due to its high efficacy, the researchers plan to incorporate phenformin into their treatment in conjunction with a Krebs cycle inhibitor, devimistat (CPI-613).
Comments
Suggestion
In your last sentence, you mention "the researchers" however have not mentioned them at all throughout the paragraph. If you are talking about a study that researchers are doing, try to incorporate/introduce that at the beginning of your paragraph too.
Suggestions
I think you should talk or explain a little bit what OXPHOS complex I Inhibitor is about just to help the reader understands the paragraph better.